You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

89Zr-DFO-REGN3767

Showing 1 - 25 of 128
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Large B-cell Lymphoma, DLBCL Trial in New York (89Zr-DFO-REGN3767, PET/CT)

Recruiting
  • Large B-cell Lymphoma
  • DLBCL
  • 89Zr-DFO-REGN3767
  • PET/CT
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Oct 3, 2022

Metastatic Solid Tumor Trial in Groningen (89Zr-DFO-REGN3767, Cemiplimab)

Recruiting
  • Metastatic Solid Tumor
  • Groningen, Netherlands
    University Medical Center Groninen
Jan 24, 2022

Advanced Solid Tumor, Metastatic Solid Tumor Trial (89Zr?DFO?REGN5054, cemiplimab)

Not yet recruiting
  • Advanced Solid Tumor
  • Metastatic Solid Tumor
  • (no location specified)
Aug 5, 2022

Multiple Myeloma, Plasma Cell Myeloma Trial in San Francisco (drug, procedure, other)

Not yet recruiting
  • Multiple Myeloma
  • Plasma Cell Myeloma
  • Zirconium Zr 89-DFO-YS5
  • +3 more
  • San Francisco, California
    University of California, San Francisco
May 26, 2023

Prostate Cancer Trial in New York (89Zr- DFO-MSTP2109A, 89Zr DFO-MSTP2109A)

Active, not recruiting
  • Prostate Cancer
  • 89Zr- DFO-MSTP2109A
  • 89Zr DFO-MSTP2109A
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Feb 1, 2023

Clear Cell Renal Cell Carcinoma Trial in Los Angeles (89Zr-DFO-girentuximab)

Available
  • Clear Cell Renal Cell Carcinoma
  • 89Zr-DFO-girentuximab
  • Los Angeles, California
    UCLA
Oct 12, 2023

Breast Cancer, Metastatic Breast Cancer, HER2-positive Breast Cancer Trial in Amsterdam (89Zr-DFO*-trastuzumab PET scan)

Recruiting
  • Breast Cancer
  • +5 more
  • 89Zr-DFO*-trastuzumab PET scan
  • Amsterdam, Noord-Holland, Netherlands
    AmsterdamUMC
Jul 12, 2023

Clear Cell Renal Cell Carcinoma, Suspected Recurrent Renal Clear Cell Carcinoma, Recurrent Renal Cell Cancer Trial

Not yet recruiting
  • Clear Cell Renal Cell Carcinoma
  • +2 more
  • (no location specified)
May 14, 2023

Amyotrophic Lateral Sclerosis Trial (89Zr-DFO-AP-101)

Not yet recruiting
  • Amyotrophic Lateral Sclerosis
  • (no location specified)
Jul 26, 2023

Lung Cancer, Colorectal Cancer Trial in Saskatoon (50 mg 89Zr-DFO-Nimotuzumab, 1 mg 89Zr-DFO-Nimotuzumab)

Recruiting
  • Lung Cancer
  • Colorectal Cancer
  • 50 mg 89Zr-DFO-Nimotuzumab
  • 1 mg 89Zr-DFO-Nimotuzumab
  • Saskatoon, Saskatchewan, Canada
    Royal University Hospital
May 18, 2022

Advanced PD-L1 Positive Malignancies Trial in New York (89Zr?DFO?REGN3504)

Terminated
  • Advanced PD-L1 Positive Malignancies
  • New York, New York
  • +1 more
Feb 7, 2022

Multiple Myeloma Trial (89Zr-DFO-daratumumab, PET/CT)

Withdrawn
  • Multiple Myeloma
  • (no location specified)
Jun 30, 2022

Rheumatoid Arthritis Trial in San Francisco (89Zr-DFO-CZP)

Suspended
  • Rheumatoid Arthritis
  • San Francisco, California
    University of California, San Francisco
Jun 7, 2022

Prostate Cancer Trial in New York (89Zr-DFO-huJ591)

Active, not recruiting
  • Prostate Cancer
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Feb 28, 2022

Esophagogastric Cancer Trial in New York (89Zr-DFO-trastuzumab, PET imaging)

Active, not recruiting
  • Esophagogastric Cancer
  • 89Zr-DFO-trastuzumab
  • PET imaging
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Dec 7, 2021

Prostate Cancer, Metastatic Castration-resistant Prostate Cancer Trial in San Francisco (drug, biological, procedure)

Recruiting
  • Prostate Cancer
  • Metastatic Castration-resistant Prostate Cancer
  • San Francisco, California
    University of California, San Francisco
Mar 29, 2022

Cervical Cancer, Colorectal Cancer, Esophageal Cancer Trial (89Zr-DFO-girentuximab)

Not yet recruiting
  • Cervical Cancer
  • +13 more
  • (no location specified)
Sep 28, 2022

Brain Cancer, Pituitary Adenoma Trial in New York (89Zr-DFO-cRGDY-PEG-Cy5-C' dots PET Imaging, Blood and Urine samples)

Recruiting
  • Brain Cancer
  • Pituitary Adenoma
  • 89Zr-DFO-cRGDY-PEG-Cy5-C' dots PET Imaging
  • Blood and Urine samples
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jan 11, 2022

Pancreatic Cancer, Tumors That Express CA19-9 Trial in United States (MVT-2163, MVT-5873)

Recruiting
  • Pancreatic Cancer
  • Tumors That Express CA19-9
  • Basking Ridge, New Jersey
  • +6 more
May 3, 2022

Multiple Myeloma Trial in New York (drug, device, other)

Completed
Has Results
  • Multiple Myeloma
  • New York, New York
    Memorial Slaon-Kettering Cancer Center
Jul 9, 2021

Solid Tumor, Adult, Advanced Solid Tumor, Advanced Renal Cell Carcinoma Trial in Australia (89Zr-TLX250, 177Lu-TLX250 and

Recruiting
  • Solid Tumor, Adult
  • +2 more
  • 89Zr-TLX250
  • 177Lu-TLX250 and Peposertib
  • North Ryde, New South Wales, Australia
  • +4 more
May 22, 2023

Pancreatic Carcinoma, Tumors That Express CA19-9 Trial in New York (MVT-2163, MVT-5873)

Terminated
  • Pancreatic Carcinoma
  • Tumors That Express CA19-9
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Aug 26, 2021

Carcinoma, Renal Cell, Clear Cell Renal Cell Carcinoma Trial in Yokohama City (89Zr-girentuximab)

Completed
  • Carcinoma, Renal Cell
  • Clear Cell Renal Cell Carcinoma
  • 89Zr-girentuximab
  • Yokohama City, Kanagawa, Japan
    Yokohama City University Hospital
Aug 18, 2021

HIV-1-infection Trial in San Francisco ([89]Zr-DFO-VRC-HIVMAB060-00-AB)

Recruiting
  • HIV-1-infection
  • San Francisco, California
    University of California, San Francisco
Mar 10, 2021

Multiple Myeloma Trial in Irvine (89Zr-daratumumab PET/CT)

Recruiting
  • Multiple Myeloma
  • 89Zr-daratumumab PET/CT
  • Irvine, California
    Hoag Memorial Hospital Presbyterian
Aug 1, 2022